The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.본 발명은 HER3 (ErbB3)에 대해 유도된 신규한 치료용 재조합 항체뿐 아니라, 상기 재조합 항-HER3 항체들 중 적어도 2개의 혼합물을 포함하는 조성물, 및 암의 치료를 위한 항체 및 항체 조성물의 용도에 관한 것이다.
